Total Payments
$41,360
2024 Payments
$2,050
Companies
16
Transactions
134
Payment Breakdown by Category
Travel$14,433 (34.9%)
Consulting$14,027 (33.9%)
Research$10,290 (24.9%)
Food & Beverage$2,586 (6.3%)
Other$25.00 (0.1%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Travel and Lodging | $14,433 | 24 | 34.9% |
| Consulting Fee | $14,027 | 5 | 33.9% |
| Unspecified | $10,290 | 37 | 24.9% |
| Food and Beverage | $2,586 | 67 | 6.3% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $25.00 | 1 | 0.1% |
Payments by Type
General
$31,070
97 transactions
Research
$10,290
37 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| GlaxoSmithKline, LLC. | $25,477 | 53 | $0 (2023) |
| PFIZER INC. | $6,211 | 13 | $0 (2023) |
| SANOFI PASTEUR INC. | $3,615 | 32 | $0 (2024) |
| Novo Nordisk Inc | $3,500 | 3 | $0 (2023) |
| Merck Sharp & Dohme LLC | $1,502 | 14 | $0 (2023) |
| Seqirus USA Inc | $732.00 | 1 | $0 (2023) |
| Shire North American Group Inc | $47.17 | 3 | $0 (2019) |
| Meridian Bioscience Inc. | $46.33 | 1 | $0 (2019) |
| AstraZeneca Pharmaceuticals LP | $46.07 | 3 | $0 (2018) |
| Tris Pharma Inc | $39.08 | 3 | $0 (2023) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $2,050 | 16 | SANOFI PASTEUR INC. ($2,006) |
| 2023 | $17,076 | 24 | GlaxoSmithKline, LLC. ($8,411) |
| 2022 | $234.92 | 8 | Novo Nordisk Inc ($124.63) |
| 2019 | $2,080 | 24 | Merck Sharp & Dohme Corporation ($1,446) |
| 2018 | $16,837 | 34 | GlaxoSmithKline, LLC. ($13,546) |
| 2017 | $3,082 | 28 | GlaxoSmithKline, LLC. ($2,983) |
All Payment Transactions
134 individual payment records from CMS Open Payments — Page 1 of 6
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/19/2024 | SANOFI US SERVICES INC. | — | — | Cash or cash equivalent | $26.80 | Research |
| Study: A Phase 3, randomized, modified double-blind, active-controlled, parallel-group, 2arm study to investigate the safety of a 4-dose regimen of a 21-valent pneumococcal conjugate vaccine in healthy infants and toddlers | ||||||
| 12/06/2024 | SANOFI PASTEUR INC. | — | — | In-kind items and services | $78.00 | Research |
| Study: A Phase 3, randomized, modified double-blind, active-controlled, parallel-group, 2arm study to investigate the safety of a 4-dose regimen of a 21-valent pneumococcal conjugate vaccine in healthy infants and toddlers | ||||||
| 12/06/2024 | SANOFI PASTEUR INC. | — | — | In-kind items and services | $58.00 | Research |
| Study: A Phase 3, randomized, modified double-blind, active-controlled, parallel-group, 2arm study to investigate the safety of a 4-dose regimen of a 21-valent pneumococcal conjugate vaccine in healthy infants and toddlers | ||||||
| 12/06/2024 | SANOFI PASTEUR INC. | — | — | In-kind items and services | $25.00 | Research |
| Study: A Phase 3, randomized, modified double-blind, active-controlled, parallel-group, 2arm study to investigate the safety of a 4-dose regimen of a 21-valent pneumococcal conjugate vaccine in healthy infants and toddlers | ||||||
| 12/05/2024 | SANOFI PASTEUR INC. | — | — | In-kind items and services | $185.00 | Research |
| Study: A Phase 3, randomized, modified double-blind, active-controlled, parallel-group, 2arm study to investigate the safety of a 4-dose regimen of a 21-valent pneumococcal conjugate vaccine in healthy infants and toddlers | ||||||
| 12/05/2024 | SANOFI PASTEUR INC. | — | — | In-kind items and services | $66.00 | Research |
| Study: A Phase 3, randomized, modified double-blind, active-controlled, parallel-group, 2arm study to investigate the safety of a 4-dose regimen of a 21-valent pneumococcal conjugate vaccine in healthy infants and toddlers | ||||||
| 12/05/2024 | SANOFI PASTEUR INC. | — | — | In-kind items and services | $58.00 | Research |
| Study: A Phase 3, randomized, modified double-blind, active-controlled, parallel-group, 2arm study to investigate the safety of a 4-dose regimen of a 21-valent pneumococcal conjugate vaccine in healthy infants and toddlers | ||||||
| 12/05/2024 | SANOFI PASTEUR INC. | — | — | In-kind items and services | $25.00 | Research |
| Study: A Phase 3, randomized, modified double-blind, active-controlled, parallel-group, 2arm study to investigate the safety of a 4-dose regimen of a 21-valent pneumococcal conjugate vaccine in healthy infants and toddlers | ||||||
| 12/05/2024 | SANOFI PASTEUR INC. | — | — | In-kind items and services | $25.00 | Research |
| Study: A Phase 3, randomized, modified double-blind, active-controlled, parallel-group, 2arm study to investigate the safety of a 4-dose regimen of a 21-valent pneumococcal conjugate vaccine in healthy infants and toddlers | ||||||
| 12/04/2024 | SANOFI PASTEUR INC. | — | — | In-kind items and services | $855.13 | Research |
| Study: A Phase 3, randomized, modified double-blind, active-controlled, parallel-group, 2arm study to investigate the safety of a 4-dose regimen of a 21-valent pneumococcal conjugate vaccine in healthy infants and toddlers | ||||||
| 12/04/2024 | SANOFI PASTEUR INC. | — | — | In-kind items and services | $381.74 | Research |
| Study: A Phase 3, randomized, modified double-blind, active-controlled, parallel-group, 2arm study to investigate the safety of a 4-dose regimen of a 21-valent pneumococcal conjugate vaccine in healthy infants and toddlers | ||||||
| 12/04/2024 | SANOFI PASTEUR INC. | — | — | In-kind items and services | $160.00 | Research |
| Study: A Phase 3, randomized, modified double-blind, active-controlled, parallel-group, 2arm study to investigate the safety of a 4-dose regimen of a 21-valent pneumococcal conjugate vaccine in healthy infants and toddlers | ||||||
| 12/04/2024 | SANOFI PASTEUR INC. | — | — | In-kind items and services | $39.21 | Research |
| Study: A Phase 3, randomized, modified double-blind, active-controlled, parallel-group, 2arm study to investigate the safety of a 4-dose regimen of a 21-valent pneumococcal conjugate vaccine in healthy infants and toddlers | ||||||
| 09/26/2024 | SANOFI PASTEUR INC. | FLUZONE QUADRIVALENT NORTHERN HEMISPHERE (Biological), BEYFORTUS | Food and Beverage | In-kind items and services | $27.89 | General |
| Category: Vaccines | ||||||
| 02/20/2024 | IRONSHORE PHARMACEUTICALS INC. | JORNAY PM (Drug) | Food and Beverage | Cash or cash equivalent | $17.68 | General |
| Category: CENTRAL NERVOUS SYSTEM STIMULANT | ||||||
| 02/12/2024 | SANOFI PASTEUR INC. | BEYFORTUS (Biological) | Food and Beverage | In-kind items and services | $21.96 | General |
| Category: Vaccines | ||||||
| 11/13/2023 | GlaxoSmithKline, LLC. | BEXSERO (Biological) | Food and Beverage | In-kind items and services | $10.43 | General |
| Category: VACCINES | ||||||
| 11/13/2023 | GlaxoSmithKline, LLC. | BEXSERO (Biological) | Food and Beverage | In-kind items and services | $0.90 | General |
| Category: VACCINES | ||||||
| 10/22/2023 | GlaxoSmithKline, LLC. | — | Food and Beverage | In-kind items and services | $56.90 | General |
| 10/18/2023 | PFIZER INC. | PREVNAR 13 (Biological) | — | In-kind items and services | $3,200.00 | Research |
| Study: PNEUMOCOCCAL VACCINE CONJ 7V CRM197 CLINICAL PUBLICATION PROGRAM • Category: VACCINES | ||||||
| 09/18/2023 | Merck Sharp & Dohme LLC | PROQUAD (Biological), VAXNEUVANCE, GARDASIL 9 | Food and Beverage | In-kind items and services | $16.50 | General |
| Category: VACCINE | ||||||
| 09/12/2023 | Tris Pharma Inc | Dyanavel XR (Drug) | Food and Beverage | In-kind items and services | $15.24 | General |
| Category: ADHD | ||||||
| 06/26/2023 | PFIZER INC. | TRUMENBA (Biological), PREVNAR 20, COMIRNATY | Food and Beverage | In-kind items and services | $16.59 | General |
| Category: VACCINES | ||||||
| 06/06/2023 | GlaxoSmithKline, LLC. | BEXSERO (Biological) | Food and Beverage | In-kind items and services | $12.19 | General |
| Category: VACCINES | ||||||
| 06/05/2023 | GlaxoSmithKline, LLC. | BEXSERO (Biological) | Food and Beverage | In-kind items and services | $1.34 | General |
| Category: VACCINES | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| PNEUMOCOCCAL VACCINE CONJ 7V CRM197 CLINICAL PUBLICATION PROGRAM | PFIZER INC. | $4,140 | 2 |
| A Phase 3, randomized, modified double-blind, active-controlled, parallel-group, 2arm study to investigate the safety of a 4-dose regimen of a 21-valent pneumococcal conjugate vaccine in healthy infants and toddlers | SANOFI PASTEUR INC. | $1,956 | 12 |
| A phase IIIA, randomized, open label, multi country study to evaluate the immunogenicity and safety of three doses of Pediarix , Hiberix and Prevenar 13 when co administered with the PCV free liquid formulation of GSK Biologicals oral live attenua | GlaxoSmithKline, LLC. | $1,191 | 12 |
| HIB 097 | GlaxoSmithKline, LLC. | $922.78 | 1 |
| A phase IIIA, randomised, observer blind, multi centre study to evaluate the clinical consistency of three production lots of the Porcine circovirus PCV free liquid formulation of GlaxoSmithKline GSK Biologicals oral live attenuated human rotavirus | GlaxoSmithKline, LLC. | $840.82 | 5 |
| MMR-162 | GlaxoSmithKline, LLC. | $640.84 | 1 |
| PREVNAR 7 CLINICAL PUBLICATION PROGRAM | PFIZER INC. | $330.00 | 1 |
| EPI-RSV-005 BOD | GlaxoSmithKline, LLC. | $241.56 | 2 |
| A Phase 3, randomized, modified double-blind, active-controlled, parallel-group, 2arm study to investigate the safety of a 4-dose regimen of a 21-valent pneumococcal conjugate vaccine in healthy infants and toddlers | SANOFI US SERVICES INC. | $26.80 | 1 |
About Dr. Peter Silas, M.D
Dr. Peter Silas, M.D is a Pediatrics healthcare provider based in Syracuse, Utah. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 07/12/2005. The National Provider Identifier (NPI) number assigned to this provider is 1295733343.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Peter Silas, M.D has received a total of $41,360 in payments from pharmaceutical and medical device companies, with $2,050 received in 2024. These payments were reported across 134 transactions from 16 companies. The most common payment nature is "Travel and Lodging" ($14,433).
Ad
Practice Information
- Specialty Pediatrics
- Location Syracuse, UT
- Active Since 07/12/2005
- Last Updated 09/05/2012
- Taxonomy Code 208000000X
- Entity Type Individual
- NPI Number 1295733343
Products in Payments
- ROTARIX (Biological) $9,639
- BEXSERO (Biological) $7,695
- PREVNAR 13 (Biological) $4,160
- MENACTRA (Drug) $1,534
- V114 (Biological) $1,446
- Saxenda (Drug) $124.63
- VYVANSE (Drug) $47.17
- SYNAGIS (Biological) $46.07
- Dyanavel XR (Drug) $39.08
- Doc Band (Device) $38.08
- FLUZONE QUADRIVALENT NORTHERN HEMISPHERE (Biological) $27.89
- NO PRODUCT DISCUSSED (Drug) $25.00
- Synagis (Drug) $23.79
- ROTATEQ (Biological) $23.47
- BEYFORTUS (Biological) $21.96
- QUILLICHEW ER (Drug) $20.43
- VAXELIS (Biological) $20.02
- JORNAY PM (Drug) $17.68
- TRUMENBA (Biological) $16.59
- PROQUAD (Biological) $16.50
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Pediatrics Doctors in Syracuse
Klaus Werner, Md, MD
Pediatrics — Payments: $29,925
Pediatrics $29,925
Dr. David Hansen, Md, MD
Pediatrics — Payments: $26,944
Pediatrics $26,944
Mrs. Wendy Holz, Msn, Cpnp, MSN, CPNP
Pediatrics — Payments: $14,632
Pediatrics $14,632
Andrea Dvorak, M.d, M.D
Pediatrics — Payments: $8,302
Pediatrics $8,302
Gloria Kennedy, Md, MD
Pediatrics — Payments: $4,160
Pediatrics $4,160
Dr. Kathleen Shefner, M.d, M.D
Pediatrics — Payments: $3,959
Pediatrics $3,959